AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 291 min read$EQ

Zedelmayer Christine sold $267K of EQ

Zedelmayer Christine (Sr. Vice President and COO) sold 95,833 shares of Equillium, Inc. (EQ) at an average of $2.79 ($2.70–$2.98, $0.27M total) across 4 trades over 2026-05-27 to 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zedelmayer Christine
Published May 29, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EQ
Bearish
medium confidence
Mentioned
$EQ
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term traders to consider selling pressure.

02

Market read

Primary insider sale filing; modest size, limited trading relevance but worth noting for short‑term sentiment.

03

What to watch

Potential upcoming corporate actions or personal tax planning may drive the sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing on 2026‑05‑29

Background

Form 4 filings disclose insider transactions; this filing reports a senior executive's sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$EQBearishMedium confidence
Context

Senior VP and COO sold 95,833 shares for $267K via a 10b5‑1 plan, reducing holdings to 62,586 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Insider sales, especially by senior executives, often lead to short‑term sell‑offs, though the amount is modest.

Market effects

Sector

Minimal impact on the broader biotech/pharma sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • company
    Equillium, Inc.

    Biopharmaceutical company whose senior executive sold shares.

  • person
    Zedelmayer Christine

    Senior Vice President and COO of Equillium, reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EQ insider trading history →

Related articles

MAY 29
$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP

dailypolitical.com7 min
SEP 29
$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $11.4M of COUR (indirect holdings)

Pale Fire Capital SE purchased 2,332,742 indirectly-held shares of Coursera, Inc. (COUR) at an average of $4.87 ($4.61–$5.06, $11.36M total) across 2 trades over 2026-09-25 to 2026-09-29. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min